Study Identifies People with Idiopathic Pulmonary Arterial Hypertension at Greatest Risk of Death

Korea began its use of effective therapies for idiopathic pulmonary arterial hypertension (IPAH) early in 2000. Idiopathic hypertension has no apparent cause. Yet there have been very few studies assessing…

Continue Reading Study Identifies People with Idiopathic Pulmonary Arterial Hypertension at Greatest Risk of Death
An Opportunity for Junior Investigators to Make an Impact on PAH Research
https://pixabay.com/photos/student-notebook-female-study-type-865073/

An Opportunity for Junior Investigators to Make an Impact on PAH Research

The Pulmonary Hypertension Association recently announced it is offering junior investigators who are interested in pulmonary arterial hypertension (PAH) a two-year grant. Pulmonary Arterial Hypertension (PAH) Pulmonary arterial hypertension (PAH)…

Continue Reading An Opportunity for Junior Investigators to Make an Impact on PAH Research
FDA Clears IND Application for Phase II Pulmonary Arterial Hypertension Trial
source: pixabay.com

FDA Clears IND Application for Phase II Pulmonary Arterial Hypertension Trial

According to a story from news.cision.com, the US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for CS1, an investigational drug being developed by the…

Continue Reading FDA Clears IND Application for Phase II Pulmonary Arterial Hypertension Trial
Study: The Effect of Patient Support Groups on Pulmonary Hypertension Patients and their Caregivers
rawpixel / Pixabay

Study: The Effect of Patient Support Groups on Pulmonary Hypertension Patients and their Caregivers

There are seven major categories of support groups including mental and emotional support, addiction, bereavement, or medical support. The latter groups are designed for patients according to a specific disease.…

Continue Reading Study: The Effect of Patient Support Groups on Pulmonary Hypertension Patients and their Caregivers
Generic Treprostinil for PAH Now Offers Subcutaneous Administration
whitesession / Pixabay

Generic Treprostinil for PAH Now Offers Subcutaneous Administration

  In 2019, generic pharmaceuticals and biosimilars leader Sandoz launched intravenous treprostinil for patients with pulmonary arterial hypertension (PAH). But according to a new media release, generic treprostinil is now…

Continue Reading Generic Treprostinil for PAH Now Offers Subcutaneous Administration
VerSIM Life Launched A Pharmaceutical Branch With A Rare Disease Mission
source: pixabay.com

VerSIM Life Launched A Pharmaceutical Branch With A Rare Disease Mission

As reported in Business Wire; VerSIM Life, a company that uses computational sciences to create novel machine learning to aid drug development, has announced that they are launching a pharmaceutical…

Continue Reading VerSIM Life Launched A Pharmaceutical Branch With A Rare Disease Mission

Researchers Work to Understand the Role of GDF15 in Lung Diseases Like Idiopathic Pulmonary Fibrosis

Growth differentiation factor 15 (GDF15) is expressed in normal conditions but is overly expressed when cells are under stress. It has multiple roles in different diseases and has been used…

Continue Reading Researchers Work to Understand the Role of GDF15 in Lung Diseases Like Idiopathic Pulmonary Fibrosis
DNMT3B Gene May Cause Pulmonary Hypertension, PAH Development
https://pixabay.com/en/stars-heart-love-mom-mother-443900/

DNMT3B Gene May Cause Pulmonary Hypertension, PAH Development

Recently, Pulmonary Hypertension News shared some burgeoning medical news: that the DNMT3B gene has now been linked to the development of pulmonary hypertension (PH) and a rare form of chronic high blood…

Continue Reading DNMT3B Gene May Cause Pulmonary Hypertension, PAH Development